Battered XenoPort Holds On For April PDUFA Date For Horizant
Executive Summary
XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.
You may also be interested in...
FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.
FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.
XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.